West Seneca, NY (PRWEB via PRWebDirect) April 29, 2008-- ANOxA CORP, a veterinary research and development company, has completed proof of concept studies of EIPHISOLTM at New Bolton Center, one of the world’s premier equine research facilities at the University Of Pennsylvania School Of Veterinary Medicine. The unique patented treatment has shown significant potential for reducing the severity of Exercised Induced Pulmonary Hemorrhage (EIPH). EIPH is a very common disorder in the equine racing industry and horses afflicted with it are known as “bleeders”. EIPH has no current FDA approved treatments and represents substantial financial losses for the racing industry and health consequences for equine athletes.
ANOxA President Herman Haenert stated, “We are very excited about our patented technology, EIPHISOL™, which promises to provide veterinarians with an effective new treatment as well as protecting the health and longevity of the equine athlete. ANOxA Corporation is currently working with the regulatory agencies to ultimately obtain FDA approval for the product.”
For additional information on EIPHISOLTM, contact Herman Haenert at hhaenert @ anoxacorp.com or visit www.anoxacorp.com.
EIPHISOL™ is a trademark of ANOxA Corporation.
ANOxA CORP, headquartered in West Seneca, New York, is a biotechnology company dedicated to Veterinary research applications.
###
|
